190 related articles for article (PubMed ID: 25341808)
1. Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients.
Peragine N; Torelli GF; Mariglia P; Pauselli S; Vitale A; Guarini A; Foà R
Cancer Immunol Immunother; 2015 Feb; 64(2):201-11. PubMed ID: 25341808
[TBL] [Abstract][Full Text] [Related]
2. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
3. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood.
Condiotti R; Zakai YB; Barak V; Nagler A
Exp Hematol; 2001 Jan; 29(1):104-13. PubMed ID: 11164111
[TBL] [Abstract][Full Text] [Related]
5. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
[TBL] [Abstract][Full Text] [Related]
6. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
[TBL] [Abstract][Full Text] [Related]
7. Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells.
Torelli GF; Peragine N; Raponi S; Pagliara D; De Propris MS; Vitale A; Bertaina A; Barberi W; Moretta L; Basso G; Santoni A; Guarini A; Locatelli F; Foà R
Haematologica; 2014 Jul; 99(7):1248-54. PubMed ID: 24658822
[TBL] [Abstract][Full Text] [Related]
8. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
[TBL] [Abstract][Full Text] [Related]
9. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.
Fujisaki H; Kakuda H; Shimasaki N; Imai C; Ma J; Lockey T; Eldridge P; Leung WH; Campana D
Cancer Res; 2009 May; 69(9):4010-7. PubMed ID: 19383914
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ
J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187
[TBL] [Abstract][Full Text] [Related]
11. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.
Carlens S; Gilljam M; Chambers BJ; Aschan J; Guven H; Ljunggren HG; Christensson B; Dilber MS
Hum Immunol; 2001 Oct; 62(10):1092-8. PubMed ID: 11600215
[TBL] [Abstract][Full Text] [Related]
12. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.
Lim O; Lee Y; Chung H; Her JH; Kang SM; Jung MY; Min B; Shin H; Kim TM; Heo DS; Hwang YK; Shin EC
PLoS One; 2013; 8(1):e53611. PubMed ID: 23326467
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.
Masuyama J; Murakami T; Iwamoto S; Fujita S
Cytotherapy; 2016 Jan; 18(1):80-90. PubMed ID: 26549384
[TBL] [Abstract][Full Text] [Related]
14. A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.
Torelli GF; Rozera C; Santodonato L; Peragine N; D'agostino G; Montefiore E; Napolitano MR; Monque DM; Carlei D; Mariglia P; Pauselli S; Gozzer M; Bafti MS; Girelli G; Guarini A; Belardelli F; Foà R
Blood Transfus; 2015 Jul; 13(3):464-71. PubMed ID: 25761309
[TBL] [Abstract][Full Text] [Related]
15. A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation.
Vasu S; Berg M; Davidson-Moncada J; Tian X; Cullis H; Childs RW
Cytotherapy; 2015 Nov; 17(11):1582-93. PubMed ID: 26432560
[TBL] [Abstract][Full Text] [Related]
16. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
17. [Method for expansion in vitro of CD3-CD56+CD16+NK cells highly purified from human peripheral blood].
Xiong D; Yang ZG; Li QH; Wu ZC; Lü JT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1310-5. PubMed ID: 21129283
[TBL] [Abstract][Full Text] [Related]
18.
Liu LL; Béziat V; Oei VYS; Pfefferle A; Schaffer M; Lehmann S; Hellström-Lindberg E; Söderhäll S; Heyman M; Grandér D; Malmberg KJ
Cancer Immunol Res; 2017 Aug; 5(8):654-665. PubMed ID: 28637877
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.
Shenouda MM; Gillgrass A; Nham T; Hogg R; Lee AJ; Chew MV; Shafaei M; Aarts C; Lee DA; Hassell J; Bane A; Dhesy-Thind S; Ashkar AA
Breast Cancer Res; 2017 Jul; 19(1):76. PubMed ID: 28668076
[TBL] [Abstract][Full Text] [Related]
20. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
